STK11 and metabolic dysfunction-associated steatotic liver disease: L-aspartic acid was negatively correlated with hepatic TG level, and L-aspartic acid treatment facilitated the LKB1-AMPK axis, accelerated lipid and cholesterol absorption and inhibited oxidative stress in hepatocytes and intestinal cells, thus ameliorating NAFLD in obese mice [8].